Bio-Techne has been making sharp strides in the bio-market capitalizing on its innovative undertakings. They recently launched an expanded menu of
RNAscope Probes for human and mouse transcriptome that advances spatial biology and a novel
GMP TcBuster Non-Viral Genome Engineering System reducing production time and costs. Positive earnings calls report strong revenue growth. Furthermore, strategic investment in
Spear Bio and strategic partnership and co-marketing agreement for
biotherapeutic characterization are important markers of success. Amidst this, Bio-Techne did see some financial instability. Their innovation business segments include the introduction of
GMP System and
ESR1 Mutation Monitoring Assay among others. They also successfully defended a claim of reverse engineering by
Miltenyi Biotec. This includes a new distribution agreement with leaders like
Life Sciences and.
Medsantek. After the Q2 2025 earnings confirmation and bold revenue projections, they have positively surprised Wall Street with robust financials, outperforming estimates and declaring dividends. There are strategists still split on whether to remain bullish or bearish but the company's stock seems steadily on the rise.
Bio-Techne Corp TECH News Analytics from Wed, 03 Mar 2021 08:00:00 GMT to Sat, 22 Feb 2025 09:36:48 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor -6
